A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
- Mechanism
- Curator reviewed
CR011 is a fully-human monoclonal antibody which utilizes antibody-drug conjugation (ADC) technology licensed from Seattle Genetics. The ADC technology links vcMMAE, a potent chemotherapeutic, to the CR011 antibody resulting in the antibody-drug conjugate CR011-vcMMAE. CR011-vcMMAE targets GPNMB, a protein located specifically on the surface of melanoma cells. After CR011-vcMMAE binds to GPNMB, it is transported inside the cancer cell where the chemotherapy payload, Auristatin E, is cleaved from the antibody and activated.
- Primary indication
- Investigated for use/treatment in melanoma.Curator reviewed
- Code names
- CDX-011 · CR-011-VCMMAE
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Glembatumumab vedotin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account